Published in Proteomics on December 12, 2012
Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res (2016) 0.85
Proteogenomics: Integrating Next-Generation Sequencing and Mass Spectrometry to Characterize Human Proteomic Variation. Annu Rev Anal Chem (Palo Alto Calif) (2016) 0.75
Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res (2008) 2.41
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene (2002) 2.09
Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays (2005) 1.97
A new strategy for identification of N-glycosylated proteins and unambiguous assignment of their glycosylation sites using HILIC enrichment and partial deglycosylation. J Proteome Res (2004) 1.65
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res (2004) 1.53
Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta (2004) 1.45
Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol (2007) 1.44
Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One (2009) 1.23
Rho GTPases: potential candidates for anticancer therapy. Cancer Lett (2004) 1.23
Candidate biomarkers in exosome-like vesicles purified from rat and mouse urine samples. Proteomics Clin Appl (2010) 1.21
Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol (2008) 1.19
Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene (2002) 1.19
Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell (2002) 1.18
Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene (2004) 1.16
Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. Mol Cancer (2009) 1.13
Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene (2003) 1.13
Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res (2005) 1.12
ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences. Mol Biol Cell (2003) 1.08
An enzymatic deglycosylation scheme enabling identification of core fucosylated N-glycans and O-glycosylation site mapping of human plasma proteins. J Proteome Res (2007) 1.07
TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann Surg Oncol (2008) 1.06
Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol (2008) 1.04
Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets (2008) 1.03
Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions. Adv Enzyme Regul (2010) 1.02
Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism. Int J Oncol (2005) 1.00
18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol (2005) 0.97
Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. Int J Biochem Cell Biol (2007) 0.95
iTRAQ-based quantitative analysis of protein mixtures with large fold change and dynamic range. Proteomics (2010) 0.95
Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol (2011) 0.94
Integrative analysis of the ubiquitin proteome isolated using Tandem Ubiquitin Binding Entities (TUBEs). J Proteomics (2011) 0.93
A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. Am J Pathol (2007) 0.93
From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett (2004) 0.92
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One (2013) 0.90
Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys (2012) 0.88
STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol Biol Cell (2003) 0.87
Comprehensive proteomic analysis of human endometrial fluid aspirate. J Proteome Res (2009) 0.86
Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog Cell Cycle Res (2003) 0.84
Virtual expert mass spectrometrist: iTRAQ tool for database-dependent search, quantitation and result storage. Proteomics (2010) 0.83
Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl (2010) 0.83
Generation and characterization of monoclonal antibodies against choline kinase alpha and their potential use as diagnostic tools in cancer. Int J Oncol (2006) 0.82
Influence of the linker in bispyridium compounds on the inhibition of human choline kinase. J Med Chem (2004) 0.82
Differential proteome profiles in E2F2-deficient T lymphocytes. Proteomics (2006) 0.82
iTRAQ-based profiling of grape berry exocarp proteins during ripening using a parallel mass spectrometric method. Mol Biosyst (2010) 0.81
Isolation and characterization of glycosylphosphatidylinositol-anchored peptides by hydrophilic interaction chromatography and MALDI tandem mass spectrometry. Anal Chem (2006) 0.80
Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium. Cancer Biol Ther (2012) 0.80
New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. J Med Chem (2004) 0.80
Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int J Oncol (2002) 0.79
Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds. Bioorg Med Chem (2002) 0.79
Human urine proteomics: building a list of human urine cancer biomarkers. Expert Rev Proteomics (2011) 0.79
Lights and shadows of proteomic technologies for the study of protein species including isoforms, splicing variants and protein post-translational modifications. Proteomics (2011) 0.78
Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase. Antimicrob Agents Chemother (2013) 0.78
Lysine methylation mapping of crenarchaeal DNA-directed RNA polymerases by collision-induced and electron-transfer dissociation mass spectrometry. J Proteome Res (2014) 0.78
Proteomic analysis of processing by-products from canned and fresh tuna: identification of potentially functional food proteins. Food Chem (2012) 0.77
Proteomics analysis of human nonalcoholic fatty liver. Methods Mol Biol (2012) 0.77
Identification of chitotriosidase isoforms in plasma of Gaucher disease patients by two dimensional gel electrophoresis. Biochim Biophys Acta (2006) 0.76
A novel 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazol with antitumoral activity via cell cycle arrest and induction of apoptosis. Int J Oncol (2004) 0.76
Clinical and Translational Oncology accepted in SciSearch and journal citation reports. Clin Transl Oncol (2008) 0.75
Non-invasive detection of drug toxicity in rats by solid-phase extraction and MALDI-TOF analysis of urine samples. Anal Bioanal Chem (2013) 0.75
Bad patients meet good drugs. Clin Transl Oncol (2006) 0.75
Anticancer research: a few hints for discovery of new targets. Cancer Lett (2004) 0.75
Computational approach for identification and characterization of GPI-anchored peptides in proteomics experiments. Proteomics (2007) 0.75